产品名称:HIV integrase抑制剂(Elvitegravir) 英文名称:Elvitegravir 产品货号:M03491 产品规格:1mL(10mM)|10mg|50mg|100mg Elvitegravir是一种HIV integrase抑制剂,作用于HIV-1IIIB,HIV-2EHO和HIV-2ROD,IC50分别为0.7nM,2.8nM和1.4nM。 注:本品仅可用于科研实验,严禁用于临床医疗及其他用途!
Elvitegravir是一种HIV integrase抑制剂,作用于HIV-1IIIB,HIV-2EHO和HIV-2ROD,IC50分别为0.7nM,2.8nM和1.4nM。注:本品仅可用于科研实验,严禁用于临床医疗及其他用途!CAS号:697761-98-1别名:GS-9137;JTK-303;EVG;D06677纯度:99.78%分子式:C23H23ClFNO5分子量:447.88结构式:储存条件:-20℃,有效期2年,溶入...
HIV-1inhibitorintegrasepeptidereverse transcriptaseMultiple clinical benefits have been obtained thanks to the combination of drugs targeting several steps of the replication. However, despite such combination therapy, complete eradication of the virus cannot be attaine...
这表明两种整合酶抑制剂之间几乎没有临床交叉耐药性。 临床应用[5][6] 作为艾滋病的常规治疗药物研究以野生HIV-1、核苷类逆转录酶抑制剂耐药HIV-1(HIV-1RT-D67N,K70R,T215F)及整合酶抑制剂耐药HIV-1(HIV-1IN-G140S,Q148H)重组病毒模型为代表,比较了以整合酶抑制剂DTG与非核苷类逆转录酶抑制剂依法韦伦(...
英文: HIV-1 integrase enzymelinked immunosorbent assay and inhibitors中文: HIV-1整合酶酶联免疫吸附试验及其抑制剂的研究 英文: Prokaryotic Soluble Expression and Functional Study of HIV-1 Integrase Protein中文: HIV-1整合酶蛋白的可溶性表达及功能研究 ...
Integrase (IN) is one of only three viral enzymes encoded by the human immunodeficiency virus (HIV). The enzymatic activity of IN catalyzes the "integration" of viral double-stranded DNA into host chromatin. Several steps including assembly, nuclear import, and gap repair are involved in the ov...
HIV-1 Integrase 英文名称:HIV-1 Integrase总访问:276 国产/进口:进口半年访问:14 产地/品牌:德国Jena产品类别:生化试剂 规格:PR-1208最后更新:2024-12-5 货号: CAS 号: 参考报价:4597 立即询价电话咨询 [发表评论][本类其他产品][本类其他供应商][收藏] ...
HIV-2 Integrase HIV-2整合酶文献(pubmed) 以下为句子列表:英文: Fusing ZAP to HIV RNA Binding Proteins to Inhibit HIV中文: ZAP融合蛋白抑制HIV病毒模型的构建及功能分析 英文: HIV antibody in plasma was screened by HIV-/ ELISA. The positive samples were analyzed by a HIV-/ Line Immuno Assay(...
产品描述Dolutegravir (GSK1349572)是一种两个金属结合的HIVintegrase抑制剂,无细胞试验中IC50为2.7nM,对耐Raltegravir的显著突变体Y143R、Q148K、N155H和G140S/Q148H具有适度的活性。 信号通路Microbiology 靶点HIV integrase--- IC502.7nM--- 体外研究S/GSK1349572对来自整合酶抑制剂-天然HIV-2感染患者的9种临床分...
The disclosure generally relates to the novel compounds of formula I, including their salts, which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions ...